Classification and Origin of Agents
Antibody agents used as immunosuppressants exhibit significant diversity. First, they are categorized by the origin of their protein molecule. Clinical practice features murine, chimeric, humanized, and fully human antibodies. Additionally, animal-derived preparations exist (e.g., rabbit or horse antibodies).
Based on mechanism of action and key targets, the main groups include:
- TNF-α inhibitors. This group includes etanercept and infliximab, as well as certolizumab pegol, adalimumab, and golimumab. The detailed pharmacological profile of these agents is typically covered under disease-modifying antirheumatic drugs (DMARDs).
- IL-2 receptor antagonists. Typical representatives are daclizumab and basiliximab.
- Polyclonal antibodies. This group includes antithymocyte globulin.
IL-2 Receptor Antagonists: Focus on Basiliximab
Basiliximab is a prime example of a chimeric monoclonal antibody. Its molecular structure is combined: it consists of 75% human amino acid sequences and 25% murine peptides. This distinguishes it from fully human or humanized analogues.
In terms of its primary pharmacological properties — clinical profile, indications, mechanism of immunosuppressive action, and adverse effect spectrum — basiliximab is identical to daclizumab. However, one critical difference exists between them: the pharmacological activity of basiliximab is exactly 10 times greater than that of daclizumab, making it a more potent targeted therapy tool.
Polyclonal Antibodies: Antithymocyte Globulin
Antithymocyte globulin (known by the trade name thymoglobulin) differs fundamentally from monoclonal antibodies. By origin, it consists of rabbit or horse polyclonal antibodies that specifically bind to human thymocytes.
The drug's mechanism of action represents a sequential cascade of reactions:
- First, the antibodies bind tightly to the surface of circulating T lymphocytes in the blood.
- Next, direct destruction of these lymphocyte cells occurs.
- The resulting fragments of destroyed cells undergo phagocytosis by macrophages in liver and spleen tissues.
- Result: Profound lymphopenia develops, accompanied by marked impairment of the immune response.
In clinical practice, thymoglobulin is prescribed for the prophylaxis of graft rejection reactions following kidney, heart, liver, or pancreas transplantation. Furthermore, the agent is effective in the combination treatment of aplastic anemia.
Safety Profile and Adverse Effects
Immunosuppressive antibody therapy requires careful monitoring due to a wide spectrum of adverse reactions.
General adverse effects include:
- Metabolic disorders: Development of hyperlipidemia.
- Gastrointestinal tract: Nausea and diarrhea.
- Hematologic shifts: Leukopenia and thrombocytopenia.
- Other reactions: Headache and potential nephrotoxicity.
When using thymoglobulin, fever, serum sickness-like reactions, and skin lesions (erythematous or pustular rashes) are frequently observed. Blood tests reveal not only thrombocytopenia but also neutropenia.
Of greatest clinical danger are severe anaphylactoid reactions. These can occur directly during drug infusion or immediately after its completion. A characteristic feature is that such reactions most frequently develop in response to the very first administration. The symptom complex includes a sharp drop in blood pressure, urticarial rash, fever, and severe respiratory distress syndrome ("shock lung" syndrome).